Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors

This study is testing whether delivering chemotherapy directly into the liver's blood supply (hepatic arterial infusion using mFOLFOX) after surgery can reduce the risk of liver cancer (hepatocellular carcinoma, or HCC) coming back in patients who have features that make recurrence more likely. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed liver cancer (hepatocellular carcinoma) and have had successful surgery to completely remove it (with clean margins) - You have not received any prior cancer treatments (chemotherapy, targeted therapy, immunotherapy, radiation) before surgery - Your cancer has at least one high-risk recurrence feature (e.g., tumor larger than 5 cm, blood vessel invasion, satellite nodules, or multiple tumors) - Your liver function, blood counts, and ECOG performance status meet study requirements **You may NOT be eligible if...** - Your cancer involves certain rare subtypes (fibrotic or mixed HCC) - Surgery was incomplete (cancer remains) - You have had prior treatment for HCC - You have severe liver disease or poor organ function Talk to your doctor to see if this trial is right for you.